Investigating unexpected INRs: In search of the culprit Adherence, interactions, genetics, and superwarfarin

Netherlands Journal of Medicine

Volumn 67, Issue 2, 2009, Pages 76-78

  Schmeits, P C J ^a   Pequeriaux N C V ^a   van Geest Daalderop, J H H ^a   Ouwehand, M E ^b   Coremans, A M J ^b   Hermans, M H A ^a   Conemans, J M H ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b BERNHOVEN HOSPITAL   (Netherlands)

Author keywords

Coumarin; CYP2C9; INR; Superwarfarin; VKORCI

Indexed keywords

ACENOCOUMAROL; ACTIVATED CARBON; BRODIFACOUM; CARBAMAZEPINE; COUMARIN DERIVATIVE; CYTOCHROME P450 2C9; DIFENACOUM; DIFETHIALONE; MENADIONE EPOXIDE; PHENPROCOUMON; RODENTICIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VITAMIN K EPOXIDE REDUCTASE C1; VITAMIN K GROUP; WARFARIN;

ANEMIA; ARTICLE; BLEEDING; BLOOD SAMPLING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INTOXICATION; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HETEROZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MISSENSE MUTATION; PATIENT COMPLIANCE; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PHARMACOGENETICS; THROMBOEMBOLISM;

4-HYDROXYCOUMARINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; DRUG INTERACTIONS; FEMALE; GENETIC VARIATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; RISK FACTORS; YOUNG ADULT;

EID: 60849135430     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):S160-98.
2. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-41.
3. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541-4.
4. Bodin L, Horellou MH, Flaujac C, Loriot MA, Samama MM. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost. 2005;3:1533-5.
5. Wilms EB, Veldkamp RF, van Meegen E, Touw DJ. Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism. Ned Tijdschr Geneeskd. 2006;150:2095-8.
6. Wilms EB, Touw DJ, Conemans JM, Veldkamp R, Hermans M. A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon. J Thromb Haemost. 2008;6:1224-6.
7. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006;80:13-22.
8. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: Interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2007;81:185-93.
9. Van Iersel MD, Blenke AA, Kremer HP, Hekster YA. A patient with lessened sensitivity to acenocoumarol during a period of enteral feeding. Ned Tijdschr Geneeskd. 2004;148:1155-7.
10. Dickerson RN. Warfarin resistance and enteral tube feeding: A vitamin K-independent interaction. Nutrition. 2008;24:1048-52.
11. Schlienger R, Kurmann M, Drewe J, Muller-Spahn F, Seifritz F. Inhibition of phenprocoumon anticoagulation by carbamazepine. Eur Neuropsychopharmacol. 2000;10(3):219-21.
12. Parrish RH, Pazdur DE, O'donnell PJ. Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: Case report and review of the literature. Pharmacotherapy. 2006;26:1650-53.
13. Bruno GR, Howland MA, McMeeking A, Hoffman RS. Long-acting anticoagulant overdose: Brodifacoum kinetics and optimal vitamin K dosing. Ann Emerg Med. 2000;36:262-7.
14. Chua JD, Friedenberg WR. Superwarfarin poisoning. Arch Intern Med. 1998;158:1929-32.
15. Mannucci PM, Spreafico M, Peyvandi F. Dosing anticoagulant therapy with coumarin drugs: Is genotyping clinically useful? No. J Thromb Haemost. 2008;6:1450-2.
16. Thacker SM, Grice GR, Milligan PE, Gage BF. Dosing anticoagulant therapy with coumarin drugs: Is genotyping clinically useful? Yes. J Thromb Haemost. 2008;6:1445-9.
17. Van der Meer FJM, Briët E, Vanderbroucke JP, Šrámek DI, Versluijs MHPM, Rosendaal F. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol. 1997;98:893-900.
18. Locadia M, van Geest-Daalderop JHH, Sprangers MAG, Hutten BA, Prins H. The relationship between adherence and quality of treatment with vitamin K antagonists. J Thromb Haemost. 2004;2:362-3.